Natera to Release Fourth Quarter and Fiscal Year 2015 Financial Results

Mar 02, 2016, 12:45 ET from Natera, Inc.

SAN CARLOS, Calif., March 2, 2016 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2015 after the market close on March 8, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.

Conference Call Information

Event:                    

Natera's Fourth Quarter and Year-End 2015 Results Conference Call 



Date:                    

Tuesday, March 8, 2016 



Time:                    

1:30 p.m. PT (4:30 p.m. ET)



Live Dial-In:          

(866) 864-2549, Domestic  




(704) 908-0477, International



Conference ID:    

49977037



Webcast:              

investor.natera.com



A webcast replay will be available at investor.natera.com.

 

About Natera

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

Contacts

Mike Brophy, 650 249 9090 ext. 1471
mbrophy@natera.com

 

SOURCE Natera, Inc.



RELATED LINKS

http://www.natera.com